SGLT2抑制剂与糖尿病患者膀胱镜检查后尿路感染的关系  

Relationship between SGLT2 inhibitor and urinary tract infection after cystoscopy in patients with diabetes mellitus

作　　者：刘杰[1] 姜博 宁刚[1] LIU Jie;JIANG Bo;NING Gang(Department of Urology,Tianjin Third Central Hospital Branch,Tianjin 300250,CHINA)

机构地区：[1]天津市第三中心医院分院泌尿外科,300250

出　　处：《江苏医药》2022年第2期158-160,共3页Jiangsu Medical Journal

摘　　要：目的 分析钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂与糖尿病患者膀胱镜检查后尿路感染的关系。方法 回顾性分析96例行膀胱镜检查的糖尿病患者资料。其中,36例(观察组)检查前后服用SGLT2抑制剂4~12个月,另外60例(对照组)从未服用此类药物。比较两组膀胱镜检查后出现尿路感染症状、尿沉渣WBC>10个/HP和尿细菌培养阳性患者比例。结果 观察组尿路感染相关指标均高于对照组,但无统计学差异(P>0.05)。结论 在对糖尿病患者进行膀胱镜等侵入性诊疗前,建议停用SGLT2抑制剂,或采取加强防治感染的措施。Objective To analyze the correlation between sodium-glucose cotransporter 2(SGLT2) inhibitor and urinary tract infection after cystoscopy in patients with diabetes mellitus.Methods The data of 96 patients with diabetes mellitus underwent cystoscopy were retrospectively analyzed, Among whome, 36 patients(group A) took SGLT2 inhibitors for 4 to 12 months before and after the examination and 60 patients(group B) had no SGLT2 inhibitors.The proportions of the patients with urinary tract infection symptoms, urinary sediment WBC>10 cells/HP,and positive urine bacterial culture after cystoscopy were compared between two groups.Results All the indexes related to urinary tract infection in group A were higher than those in group B,but which had no statistical differences(P>0.05).Conclusion Before taking the invasive measures for diagnosis and treatment such as cystoscopy for the patients with diabetes mellitus, it is recommended to discontinue the use of SGLT2 inhibitors, or take some measures to strengthen the prevention and control of infection.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 膀胱镜 尿路感染 

分 类 号：R691[医药卫生—泌尿科学]